Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Non-Current Assets (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Non-Current Assets for 4 consecutive years, with $22.7 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets rose 11.1% to $22.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $96.9 million through Dec 2025, up 66.53% year-over-year, with the annual reading at $22.7 million for FY2025, 11.1% up from the prior year.
  • Non-Current Assets for Q4 2025 was $22.7 million at Day One Biopharmaceuticals, down from $23.8 million in the prior quarter.
  • The five-year high for Non-Current Assets was $25.7 million in Q1 2025, with the low at $611000.0 in Q1 2024.
  • Average Non-Current Assets over 4 years is $13.2 million, with a median of $18.5 million recorded in 2024.
  • The sharpest move saw Non-Current Assets crashed 34.85% in 2023, then soared 4107.04% in 2025.
  • Over 4 years, Non-Current Assets stood at $1.2 million in 2022, then plummeted by 34.85% to $774000.0 in 2023, then surged by 2543.15% to $20.5 million in 2024, then increased by 11.1% to $22.7 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $22.7 million, $23.8 million, and $24.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.